Related Experiment Video
Updated: Jun 22, 2026

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
[Role of anidulafungin in critically ill patients]
Márcio Borges Sá1, José Garnacho Montero
1Unidad de Cuidados Críticos, Servicio de Medicina Intensiva, Hospital Son Llátzer, Palma, Islas Baleares, España. mborges@hsll.es
Abstract:
The most frequent invasive fungal infections in critically ill patients are invasive candidiasis, among which is candidemia. In the last few years, these infections have become more common in intensive care units (ICU), including those produced by species other than Candida albicans. This phenomenon may lead to the development of species resistant to antifungal agents. To start the most appropriate treatment, early diagnosis of the infection is essential, which would reduce empirical antibiotic treatment and increase the proportion of advanced or directed antibiotic therapy. Given the poor reliability of the available diagnostic techniques, new strategies are currently being employed in the ICU, such as the use of scores to evaluate the presence of fungal infections. The therapeutic arsenal against these infections has been increased and the introduction of anidulafungin represents the addition of a highly appropriate drug for the treatment of invasive candidiasis in immunocompetent critically ill patients.
Insights
Invasive fungal infections, particularly candidemia, are increasing in ICUs, necessitating early diagnosis and new treatments. Anidulafungin offers a new option for immunocompetent patients with invasive candidiasis.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Mycology
Background:
- Invasive fungal infections, especially invasive candidiasis and candidemia, are prevalent in critically ill patients.
- There is a rising incidence of non-albicans Candida species causing infections, potentially leading to antifungal resistance.
- Current diagnostic methods for invasive fungal infections lack reliability, impacting timely and appropriate treatment.
Purpose of the Study:
- To highlight the increasing challenge of invasive fungal infections in intensive care units (ICUs).
- To emphasize the need for early and accurate diagnosis to guide therapy.
- To introduce anidulafungin as a new therapeutic option for invasive candidiasis.
Main Methods:
- Review of current literature on invasive fungal infections in ICUs.
- Discussion of diagnostic challenges and emerging strategies like clinical scores.
- Evaluation of the therapeutic landscape, including new antifungal agents.
Main Results:
- Invasive candidiasis, including candidemia, is a growing concern in ICUs, with non-albicans species becoming more common.
- Antifungal resistance is a potential consequence of increased infection rates and empirical treatment.
- New diagnostic approaches and therapeutic agents are crucial for managing these infections.
Conclusions:
- Early diagnosis of invasive fungal infections is essential to optimize patient treatment and outcomes in the ICU.
- Anidulafungin is a valuable addition to the treatment options for invasive candidiasis in immunocompetent critically ill patients.
- Continued research into diagnostics and therapeutics is vital to combat rising rates of invasive fungal infections.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Acute Pyelonephritis II: Diagnostic Studies and Management
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Fungal Phylum Microsporidia
